关于房颤或房扑对NT-proBNP血浆浓度的影响及其与治疗效果的关系,预设亚组分析结果已经表明,治疗对主要结局(180天HF再入院或死亡)的影响在筛查时有无房颤或房扑病史的患者之间没有统计学差异(风险差异6.1% vs. 9.8%,交互作用P=0.50)。...
《柳叶刀》一项研究“Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial”探讨了关于急性心力衰竭指南指导...
Blood pressure and intensive treatment up‐titration after acute heart failure hospitalization: Insights from the STRONG‐HF trialHeart failureAcute heart failureBlood pressureMedical therapyRandomized trialAims A high-intensity care (HIC) strategy with rapid guideline-directed medical therapy (GDMT...
About the STRONG-HF Trial Trial Name: Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies ClinicalTrials.gov ID: NCT03412201 Sponsor: Heart Initiative Study Estimated Completion: October 2021 Individuals who were assigned...
of Heart Failure Therapies (STRONG-HF) trial demonstrated that a high-intensity care (HIC) strategy of rapid GDMT up-titration and close follow-up can decrease the risk of 180-day HF readmission or all-cause death in patients recently hospitalized for acute HF, compared with usual care (UC)...
Findings In this secondary analysis of the Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by N-Terminal Pro–Brain Natriuretic Peptide Testing of Heart Failure Therapies (STRONG-HF) randomized clinical trial including 515 patients, 2 weeks after discharge, medium- to high-dose GDMT...
Apply For Free Trial DetailOrder InformationDocuments Product Q Captarose HF Q Captarose HR Q Singarose FF Q Singarose HP Q Singarose XL Q Singarose BB Features High rigidity, pressure-resistant, fast flow rate High resolution, low backpressure ...
三、如何提高GDMT治疗的达标率,改善心衰患者的治疗结局?STRONG-HF研究 《 柳叶刀 》一项研究“Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial”探讨了关于急性心力衰竭指南指导的药物...
The corresponding effect size (partial eta squared) was > 0.3, achieving power over 90%; however, significant decreases in HF and LF were observed only in the late phase. The PPG amplitude was increased significantly in both the early and late phases. Conclusion: Propofol induction results in ...
A phase 1/2 trial showed that SLS009 in combination with azacitidine and venetoclax achieved a 50% response rate in relapsed/refractory acute myeloid leukemia.